TITLE

Impact of change in practice: pharmacist-led respiratory syncytial virus (RSV) immunoprophylaxis clinic

AUTHOR(S)
Vaghela, T.; Ramesh, C.
PUB. DATE
April 2011
SOURCE
Archives of Disease in Childhood -- Fetal & Neonatal Edition;Apr2011, Vol. 96 Issue 4, pe1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective To measure the impact of a new Pharmacy-Led RSV immunoprophylaxis clinic on hospital admission rates in high-risk infants with RSV bronchiolitis. Method Retrospective data was collected for all infants who attended the clinic from 2006/7 to 2009/10. Using a standardised form, clinic attendance, adverse events and hospital admission with respiratory syncytial virus (RSV) bronchiolitis during RSV season were documented. Preclinic data for the season 2004/5 and 2005/6 were collected along with adverse events and hospital admission with RSV bronchiolitis. Results All infants received palivizumab in accordance with the local peri-natal network guidelines.1 Conclusion The results show that in the 4 years since the implementation of the clinic there have been no hospital admissions of high risk infants with RSV bronchiolitis. This is in contrast to the preclinic results where 5 out of 15 infants were admitted over a 2 year period. The reduction in the number of high risk infants admitted with RSV bronchiolitis following the introduction of the pharmacist-led clinic may be due to a number of factors. One major contributing factor is parental education. At the initial visit the pharmacist provides information on palivizumab, discusses the risk factors associated with development of severe RSV bronchiolitis and provides information on how to minimise these risk factors. Another contributing factor may have been a more accurate dosing of palivizumab at correct intervals. In the clinic the baby is weighed and then the pharmacist prescribes the accurate dose which is administered immediately by the nurse. In contrast to the pre clinic, at the clinic palivizumab was administered at regular 28 days intervals. View this table: • In this window • In a new window Additional benefits seen in the clinic have been a reduction in nursing time and a reduction in drug costs of palivizumab through efficient usage of the less expensive 100 mg vials. Experience and feedback from parents from the clinic over the last 4 years has shown that the parents value a specialist pharmacist advice in addition to nursing and medical advice. This multidisciplinary clinic has been successful in delivering efficient immunoprophylaxis programme by providing a structured approach to the management of infants at high risk of developing severe RSV bronchiolitis. The pharmacy-led clinic has made an impact by demonstrating the value of a supplementary/independent-prescriber pharmacist in delivering improved patient care.
ACCESSION #
61211352

 

Related Articles

  • Vitamin A for treatment of acute RSV infection. Sadovsky, Richard // American Family Physician;1/1/1997, Vol. 55 Issue 1, p282 

    Summarizes a study by J.S. Bresee, et al, which appeared in the `Pediatric Infectious Disease Journal' of 1996, volume 15, that evaluated the effectiveness of high-dose Vitamin A in the treatment of acute respiratory syncytial virus (RSV) infection. Background on the study; Outline of results;...

  • For babes in the woods. Portyansky, Elena // Drug Topics;7/20/98, Vol. 142 Issue 14, p20 

    Presents information relating to the dangers associated with the respiratory syncytial virus (RSV) on babies, while highlighting the introduction of the drug, medlmmune's synagis (palivizumab) in the treatment of the disease. Inclusion of therapeutic options available; Benefits concerning the...

  • New Weapon to Fight RSV. Lee, Michelle // Parenting;Nov98, Vol. 12 Issue 9, p39 

    Reports that an injection drug to prevent respiratory syncytial virus (RSV) in children has been approved by the Untied State Food and Drug Administration (FDA). What RSV results in; Name of the injection; Identification of the RSV season.

  • Space Research Aids Study of Deadly Virus.  // USA Today Magazine;Oct98, Vol. 127 Issue 2641, p3 

    Reports that the United States National Aeronautics and Space Administration (NASA) and biotechnology researchers have taken steps toward developing a treatment for a virus that causes pneumonia and severe upper respiratory infection in infants and young children. Information on the respiratory...

  • Breathe easy. Day, Michael // New Scientist;06/13/98, Vol. 158 Issue 2138, p22 

    Reports that mutant viral protein may be tried as a vaccine for asthma. Theory that respiratory syncytial virus (RSV) may be a cause of asthma; Number of children in British cities that require hospital treatment for RSV; Research by Peter Openshaw of Imperial College School of Medicine in...

  • AAP revisions to monoclonal antibody dosage explained. Cona, Christen; DeNyse, Ashley; Richards, Cassandra A.; Shafer, Emily // Infectious Diseases in Children;Dec2010, Vol. 23 Issue 12, p19 

    The article focuses on the revisions made on the guidelines issued by the American Academy of Pediatrics (AAP) for the administration of monoclonal antibodies to treat respiratory syncytial virus (RSV) in children.

  • Palivizumab recommendations for use in high-risk infants updated in new Red Book.  // Infectious Diseases in Children;Aug2009, Vol. 22 Issue 8, p24 

    The article focuses on the updated recommendations for immunoprophylaxis with palivizumab for the treatment of respiratory syncytial virus which was published in the "2009 AAP Red Book."

  • Bronchiolitis: First do no harm. McMillan, Julia A. // Contemporary Pediatrics;Feb2008, Vol. 25 Issue 2, p13 

    An introduction to articles published within the issue is presented, including an article on the recommended treatment for respiratory syncytial virus (RSV) and bronchiolitis.

  • A survey of palivizumab for infants with cystic fibrosis in the UK. McCormick, J.; Southern, K. W. // Archives of Disease in Childhood;Jan2007, Vol. 92 Issue 1, p87 

    A letter to the editor is presented in response to the article "Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants," by the IMpact RSV Study Group that appeared in a previous issue of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics